| Indicators | Browse All

Curis, Inc. (CRIS)

Healthcare | Biotechnology | Lexington, United States | NasdaqCM
4.75 USD -0.21 (-4.234%) ⇩ (July 13, 2026, 4 p.m. EDT)
After hours: 4.76 +0.01 (0.211%) ⇧ (July 13, 2026, 5:44 p.m. EDT)

Short-term:★★⯪☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 5:15 a.m. EDT

The immediate outlook is clouded by extreme volatility and a catastrophic long-term trajectory. While the stock recently rallied from sub-dollar levels to nearly $6, this surge appears to be a technical anomaly rather than a fundamental reversal, given the persistent negative earnings, massive losses, and a balance sheet that barely covers its obligations. The most alarming indicator is the multi-year price history: the asset has suffered four consecutive years of decline, erasing over 98% of its value since 2016. This structural deterioration suggests the market has permanently reassessed the business quality downward, rendering any 'value' narrative moot. With no dividend to provide income and a forward P/E that implies negative earnings growth, there is no safety margin here. The recent price spike is likely noise in a sea of red, making this a dangerous hold for both short-term traders seeking momentum and long-term investors looking for recovery.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.533712
AutoARIMA0.533712
MSTL0.535557
AutoTheta0.605705

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 8%
H-stat 288.30
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 1.76
Attribute Value
Sector Healthcare
Debt to Equity Ratio 10.522
Revenue per Share 8.895
Market Cap 9,257,436
Forward P/E -0.20
Beta 3.07
Profit Margins -299.66%
Website https://www.curis.com

Info Dump

Attribute Value
52 Week Change -0.8680851
Address1 Building C
Address2 Suite 500 128 Spring Street
All Time High 54,500.0
All Time Low 3.6
Ask 4.79
Ask Size 1
Average Daily Volume10 Day 895,245
Average Daily Volume3 Month 170,988
Average Volume 170,988
Average Volume10Days 895,245
Beta 3.071
Bid 4.93
Bid Size 1
Book Value 6.354
City Lexington
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 4.75
Current Ratio 1.109
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 5.1
Day Low 4.52
Debt To Equity 10.522
Display Name Curis
Dividend Date 1,527,638,400
Earnings Call Timestamp End 1,778,617,800
Earnings Call Timestamp Start 1,778,617,800
Earnings Timestamp 1,778,616,000
Earnings Timestamp End 1,786,478,400
Earnings Timestamp Start 1,786,478,400
Ebitda -34,146,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.129
Enterprise To Revenue -0.624
Enterprise Value -4,406,559
Eps Current Year -31.2
Eps Forward -23.73333
Eps Trailing Twelve Months -11.6
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 9.1338
Fifty Day Average Change -4.3837996
Fifty Day Average Change Percent -0.47995356
Fifty Two Week Change Percent -86.80851
Fifty Two Week High 39.0
Fifty Two Week High Change -34.25
Fifty Two Week High Change Percent -0.8782051
Fifty Two Week Low 3.6
Fifty Two Week Low Change 1.1500001
Fifty Two Week Low Change Percent 0.31944448
Fifty Two Week Range 3.6 - 39.0
Financial Currency USD
First Trade Date Milliseconds 965,136,600,000
Float Shares 1,376,962
Forward Eps -23.73333
Forward P E -0.20014048
Free Cashflow -13,806,625
Full Exchange Name NasdaqCM
Full Time Employees 20
Gmt Off Set Milliseconds -14,400,000
Gross Margins -2.7249
Gross Profits -19,246,000
Has Pre Post Market Data 1
Held Percent Insiders 0.08031
Held Percent Institutions 0.40500998
Implied Shares Outstanding 1,948,934
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,783,296,000
Last Split Factor 1:20
Long Business Summary Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Long Name Curis, Inc.
Market us_market
Market Cap 9,257,436
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_27159
Most Recent Quarter 1,774,915,200
Net Income To Common -21,165,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 9,825,940
Number Of Analyst Opinions 3
Open 4.93
Operating Cashflow -28,950,000
Operating Margins -4.8512
Payout Ratio 0.0
Phone 617 503 6500
Post Market Change 0.010000229
Post Market Change Percent 0.21053113
Post Market Price 4.76
Post Market Time 1,783,979,065
Previous Close 4.96
Price Eps Current Year -0.15224358
Price Hint 4
Price To Book 0.74756056
Price To Sales Trailing12 Months 1.3106946
Profit Margins -2.9966002
Quick Ratio 1.002
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.21
Regular Market Change Percent -4.23387
Regular Market Day High 5.1
Regular Market Day Low 4.52
Regular Market Day Range 4.52 - 5.1
Regular Market Open 4.93
Regular Market Previous Close 4.96
Regular Market Price 4.75
Regular Market Time 1,783,972,801
Regular Market Volume 89,864
Return On Assets -0.62062
Return On Equity -6.93934
Revenue Per Share 8.895
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 1,948,934
Shares Percent Shares Out 0.09020001
Shares Short 175,791
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 14,180
Short Name Curis, Inc.
Short Percent Of Float 0.0911
Short Ratio 0.42
Source Interval 15
State MA
Symbol CRIS
Target High Price 400.0
Target Low Price 100.0
Target Mean Price 280.0
Target Median Price 340.0
Total Cash 15,001,000
Total Cash Per Share 7.697
Total Debt 1,337,000
Total Revenue 7,063,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -11.6
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 18.66245
Two Hundred Day Average Change -13.912451
Two Hundred Day Average Change Percent -0.7454782
Type Disp Equity
Volume 89,864
Website https://www.curis.com
Zip 2,421